Supertake
Illustration for Peptides Go Mainstream

Peptides Go Mainstream

sufi@yusuf
· 1

+1.9%

since Oct 29

Practice

The idea

I believe peptide drugs like retatrutide are headed for the mainstream, and this plays out over years, not quarters. I own the whole chain: the big drugmakers at 34% led by Lilly for reta and tirzepatide, consumer nutrition brands riding the same wave at 24%, the pen and manufacturing suppliers that profit no matter which drug wins at 23%, and smaller next-gen biotechs at 11%, with 8% in cash. Spreading it across the chain means I'm not betting everything on one company's FDA timeline. I'd rethink this if the supplier and consumer layers stopped growing even as the drugs themselves succeed.

What it owns

  • · , , , 34%
  • · , , , , , 24%
  • · , , , , 23%
  • · , , 11%
  • Cash8%